FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
The Pharma Data
DECEMBER 15, 2020
The most common adverse events were application site pruritus and pain reported by 9% and 10% of treated patients, respectively. TWO) for actinic keratosis in Taiwan and has partnered with Xiangxue Pharmaceuticals (SHE:300147) for actinic keratosis in China, Hong Kong, and Macau. Wash hands immediately after application.
Let's personalize your content